Key findings of the landscape analysis included:
- Of the 22 companies developing advanced therapies in Australia, the majority are based in Victoria.
- Therapies include CAR-T and pluripotent stem cell derived therapies (including CAR-NK), and in vivo gene therapies.
- Dedicated clinical trial units are world-leading.
- Investment at national and State level has led to innovation hubs linked to cGMP manufacturing capabilities.
Download the full report by the University of Melbourne Stem Cell network and HOYA consulting to read about advanced therapy development nationally, and where Australia sits in the global context.